Pablo Cagnoni, M.D.

Dr. Cagnoni is president and CEO of Rubius Therapeutics. Previously, he was president and CEO of Tizona Therapeutics, a biotech company focused on developing next-generation immunotherapies fdor the treatment of cancer. Over the course of his career, Dr. Cagnoni played a key role in the development and commercialization of more than 20 life-changing treatments, including Afinitor, Kyprolis, and Tarceva.

  • March 2022

Added to: Laronde

Laronde , the company pioneering Endless RNA, a novel engineered form of RNA that can be programmed to exprss therapeutic proteins inside the body,